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Circulating autoantibodies against glutamatergic N-methyl-D-aspartate receptor (NMDAR-
Ab) have been reported in a proportion of patients with psychotic disorders, raising hopes 
for more appropriate treatment for these antibody-positive patients. However, the 
prevalence of circulating NMDAR-Ab in psychotic disorders remains controversial with 
detection prevalence rates, and immunoglobulin (Ig) classes, varying considerably between 
studies, perhaps because of different detection methods. Here, we compared the results of 
serum assays for a large cohort of first episode psychosis patients (FEP) using classical cell-
based assays in three labs and a single molecule-based imaging method. Most assays and 
single molecule imaging in live hippocampal neurons revealed the presence of circulating 
NMDAR-Ab in approximately 5% of FEP patients. However, some heterogeneity between 
cell-based assays was clearly observed, highlighting the urgent need of new sensitive 
methods to detect the presence of low-titer NMDAR-Ab in seropositive patients that cannot 
be clinically identified from seronegative ones. 
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The detection of autoantibodies against neurotransmitter receptors in patients with 
neurological and psychiatric disorders has raised hopes for a better understanding of the 
molecular cascades underlying these pathologies and for treating patients who are antibody-
positive with immunotherapy (1).  The link between psychotic disorders and autoimmunity is, 
in fact, an old concept that has regained strong support partly thanks to the discovery of anti-
N-methyl-D-aspartate receptor (NMDAR) encephalitis (2). In this disorder, autoantibodies 
directed against the GluN1 subunit of NMDAR (NMDAR-Ab) are strongly associated with 
psychotic symptoms, sometimes catatonia, and profound reversible neurologic deterioration 
(2). Remarkably, approximately 80% of patients recover with immunotherapy directed to 
remove the antibodies and antibody-producing plasma cells (corticosteroids, intravenous 
immunoglobulins, plasma exchange, rituximab, or cyclophosphamide). The process of 
recovery is slow, spanning over months, with initial improvement of autonomic dysfunction, 
and gradual improvement of deficits of memory, attention, and behavior (3). In patients with 
schizophrenia, the prevalence and clinical significance of circulating NMDAR-Ab remains 
controversial with detection prevalence rates varying considerably between studies (4). 
Recent articles reported the presence of NMDAR-Ab in schizophrenic patients using a 
detection method that has provided different outcomes in schizophrenic or FEP patients in 
the past (5-8). The extent to which discrepancies reflect different sensitivities between labs or 
between NMDAR-Ab assays is unclear (9). Moreover, most assays depend on demonstrating 
the presence of antibodies binding to the NMDAR, but do not address whether the antibodies 
significantly alter the expression, localization or function of the NMDAR. In the present study, 
we discuss and address these key issues by using three different assays to assess 
independently samples from the same patients with FEP. We also employ an innovative single 
nanoparticle-imaging method to examine the presence of such autoantibodies.   
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Methods and materials  
Participants 
From the OPTiMiSE cohort, 298 FEP patients, having minimal or no exposure to anti-
psychotics, were examined (Table 1).  
 
NMDAR-Ab detection using cell-based assays (CBA) 
Live CBA 
Serum samples were first tested for the presence of NMDAR-Ab in Lab A (Lyon) using a cell-
based assay on human embryonic kidney cells (HEK293) ectopically expressing both GluN1 
and GluN2B-NMDAR subunits, as previously described (10). Briefly, HEK293 were grown on 
glass coverslips in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal calf serum. 
24h later, cells were co-transfected (Lipofectamine LTX, Invitrogen) with plasmids coding for 
GluN1-GFP (Green Fluorescent Protein) and GluN2B subunits of the NMDAR. The co-
transfection rate was not assessed in each sample as we previously validated that most cells 
efficiently co-express the different cDNA constructs. To prevent cytotoxicity, cells were 
supplemented with 500 µM ketamine. 48h after transfection, cells were subsequently 
incubated in a saturation buffer (DMEM, 25mM HEPES, 1% BSA, 5% normal goat serum) for 
1h and with patient serum at an initial 1:20 dilution for 2h at room temperature. Cells were 
then washed in DMEM HEPES and fixed (1% paraformaldehyde, 15 min) before incubation 
with Cy3-conjugated anti-human IgG for 1h. Finally, cells were washed in phosphate 
buffered saline (PBS) and DMEM-HEPES, and mounted on slides in Mowiol mounting 
medium. Binding of human IgG to live NMDAR-expressing HEK293 cells was visualized using 
an epifluorescence microscope (Axiophot, Zeiss) and was scored from 0 to 4 according to the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
percentage of transfected cells (green) colocalized with human IgG staining (red) as 
following: negative (0 = no binding), weak positive (binding to a low percentage of 
transfected cells, <2) and positive (>2). All samples were tested by two independent blinded 
observers and all positive and weakly positive sera were retested. The final score was the 
mean of the scores of the independent assays from the 2 blinded scorers.  
 
All Lab A positive samples were tested in Lab B (Nuffield Department of Clinical 
Neurosciences, Oxford) using a similar live CBA, as described previously (11).  In this case, 
HEK293 cells were transfected with plasmids containing cDNAs of the NMDAR subunits 
GluN1 and GluN2B at a ratio of 1:3, along with an independent plasmid expressing eGFP. 
Cells were incubated in human serum at an initial 1:20 dilution for 1h at room temperature 
before fixation with 4% formaldehyde, followed by 45 min incubation with Alexa Fluor 
568 goat anti-human IgG (Invitrogen anti-IgG heavy and light chains). Binding of human IgG 
to the cell membrane of live HEK293 cells (i.e. those expressing eGFP) was assessed using an 
epifluorescence microscope (Leica DM2500); intensity of fluorescence of each sample was 
rated on a visual scoring system of 0-4. Scores of 0 and 1 were rated as negative, 1.5 as weak 
positive and 2-4 as positive. All positive samples were repeated at dilutions of 1:20, 1:100 
and 1:500 to confirm IgG specificity using goat anti-human IgG Fc, followed by AlexaFluor 
568 donkey anti-goat IgG (Invitrogen), and also checked for non-specific binding using 
HEK293 cells that had been transfected with another antigen. The titer of the antibody was 
given as the dilution of serum giving a score of 1.   
 
Euroimmun CBA kit 
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In order to assess potential sensitivity and specificity differences between live and fixed CBA, 
all positive sera identified in Lab A were also tested in Lab C (King’s College, London) using 
the commercial CBA kit (Euroimmun AG, Luebeck, Germany).  Schematically, this kit uses 
acetone-prefixed cells (to enable transport) expressing the GluN1a subunit only, which 
mostly form intracellular GluN1-NMDAR homomers (membrane homomers are possible).  
Small chips of the cells are placed onto glass cover slips and sold for detection of antibodies 
to the NMDAR (12) using in-house reagents. The cells were incubated for 30 min in human 
serum at an initial 1:10 dilution, followed by fluorescein-labelled anti-human IgG. Binding of 
IgG to transfected cells was assessed using fluorescence microscopy, and rated as positive or 
negative. All samples were scored by two independent scorers along with positive control 
samples supplied by the manufacturers. Slides were further reviewed (coded) by a final 
scorer at another laboratory (University College London, Department of Neuroimmunology) 
which performs the assay as part of routine clinical testing. Positive samples were tested 
again at dilutions of 1:100 and 1:1000 and the final titer was calculated according to 
manufacturer instructions. 
 
IgG purification and live CBA  
As human serum contains a myriad of molecules and generates high fluorescence background 
in any cultured cell systems, IgG were puriﬁed (concentrations 1.44 – 4.04 mg/ml) as 
previously described (13) from all positive sera of patients with a first psychotic episode. All 
samples were dialyzed against PBS and solutions were used at pH 7.4. To further confirm the 
presence of IgG directed against NMDAR, lab A (Lyon) performed an additional live CBA using 
purified IgG from the positive sera (Figure 1A). The concentration of the purified patient IgG 
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used for the assay was, on average, 165 µg/ml. The term “IgG” relate thus to the IgG purified 
from patients. 
 
NMDAR-Ab detection using single nanoparticle imaging 
To ascertain the presence of NMDAR-Ab, we performed single nanoparticle detection on live 
cultured rat hippocampal neurons (10). Live cultured hippocampal neurons were incubated 
for 10 min at 37°C with either purified IgG from seropositive patients (5 µg/ml, 2/6 positive 
and 3/4 weak positive samples randomly selected among the 14 samples) or a commercial 
anti-GluN1 antibody (Alomone, 5 µg/ml). Neurons were then washed and incubated for 10 
min with QD655 rabbit F(ab')2 anti-human IgG (Invitrogen, 1:5000) or QD655 goat F(ab')2 
anti-rabbit IgG (Invitrogen, 1:5000). Non-specific binding was blocked by adding BSA 1% 
(Vector Laboratories) to the QD solution. QDs were illuminated by using a mercury lamp and 
appropriate excitation/emission filters, and fluorescence signals were detected using an EM-
CCD camera (Evolve, Photometrics). Images were obtained with an acquisition time of 50 ms 
with up to 500 consecutive frames (Metamorph, Universal Imaging Corp). By fitting the 
fluorescence signal to a 2D Gaussian function, QD-anti-IgG/IgG complexes were localized with 
a 20 nm pointing accuracy and their 2D trajectories were constructed by correlation analysis 
between consecutive images using a Vogel algorithm. Surface diffusion parameters were 
extracted from each 2D trajectory: i) the Mean Square Displacement (MSD) over time, which 
represents the area explored by the receptor over time and illustrates the type of diffusion 
undergone by the receptor (e.g. freely-diffusing or confined), and ii) the instantaneous 
diffusion coefficient, D (µm
2
/s), which reflects the mobility of the receptor within the plasma 
membrane, was calculated from linear ﬁts of the ﬁrst four points of the MSD versus time 
function such as: MSD(t)=<r2>(t)= 4Dt.   
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Statistics 
All values are expressed as mean ± SEM. Comparisons between groups were performed with 
non-parametric Mann-Whitney or Kolmogorov-Smirnov (distributions) tests. Signiﬁcance 
levels were deﬁned as *p<0.05, **p<0.01, ***p<0.001 
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Results 
Detection of NMDAR-Ab in the sera of first-episode psychotic patients using different assays 
Part of the Optimise project, 298 FEP patients were recruited during their hospitalisation and 
included after approval by ethical committee and written informed consent for their 
participation (Table 1). A live CBA was first performed to determine the presence of circulating 
NMDAR-Ab in the whole cohort. Of the 298 sera tested in Lab A using an in-house live CBA 
(Figure 1A), 14 bound to NMDAR-expressing HEK293 cells (Figure 1B), with 8 samples scored 
as positive and 6 samples as weak positive according to the visual scoring scale (see Methods 
section); there was no obvious clinical differences between seropositive and seronegative 
patients (Table 1). In order to compare the results between antibody detection methods, we 
then used either live or fixed CBAs, performed in three independent laboratories, on these 
positive samples (Figure 1A). The 14 sera were then retested in Lab B using in-house live CBA. 
This second independent assay  detected IgG antibodies binding to the NMDAR in 9 samples, 
and 5 sera that were negative or below the threshold defined for positivity in clinical testing 
(Figure 1C), with a very good correlation between the scores from the two laboratories (Figure 
1D). Noteworthy, the negative samples of Lab B correspond to the weak positive ones of lab 
A, suggesting some minor appreciation difference between labs. In contrast to these 
outcomes, the fixed CBA performed in Lab C detected only 1 positive and 1 weak positive sera 
out of the 14 samples (Figure 1C). Indeed, one of the two “positive” samples titrated to 1:10 
only (weak positive) and the other to 1:10 and 1:100 (positive), suggesting much lower 
sensitivity of the fixed cells, at least for IgG antibodies detection.  
An additional live CBA using purified IgG from these 14 seropositive samples was performed in 
Lab A. Purified IgG from anti-NMDAR encephalitis patients were used as a positive control to 
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validate the assay (Figure 1B). 8 out of 14 purified IgG samples were found to be positive (3 
weak binding), consistent with the previous serum scores obtained in Lab A and B (Figure 1C).  
Furthermore, from the 8 positive patients from live CBA (Lab A), 5 were in the purified IgG 
assay (the other being border lines); from the 5 positive patients from live CBA (Lab B), 4 of 
them correspond to the positive ones in the purified IgG assay (Lab A). To note, we did not 
look for IgM and IgA antibodies. Overall, the results clearly demonstrate that seropositivity is 
highly influenced by the detection method selected, and various in-house criteria for 
positivity, with fixed CBA showing low detection rates for IgG NMDAR-Abs from FEP patients.  
 
Single nanoparticle imaging as a sensitive antibody detection test 
Live CBA might not be sensitive enough to detect low titers. In order to further confirm that 
there were NMDAR-Ab in the samples, we took advantage of the single nanoparticle imaging 
technique to characterize the behavior of patients’ purified IgG on NMDARs in live 
hippocampal neurons (Figure 2A-C). Indeed, single nanoparticle imaging gives access to the 
diffusion properties of individual labelled receptors over time (14) through a specific high-
affinity ligand-target receptor interaction that recognizes the extracellular domain of the 
molecular target in live cells. In addition, labelling needs to be performed at low QD densities 
so that it can be optically resolved (typically <1 molecule/µm
3
) and to avoid cross-linking in 
the case of multivalent ligands (e.g. antibody). Hence, the molecular behaviour of membrane 
target(s) detected by QD/IgG complexes is virtually independent of the IgG concentration 
present in the sample, contrary to classical CBA. In this assay, purified IgG from 5 out of the 14 
seropositive samples (randomly selected from both positive and weak positive samples) were 
directly coupled to fluorescent nanoparticles called Quantum Dots (QDs). The surface 
dynamics of such QD-purified IgG’s membrane target(s) were then compared to those of 
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endogenous GluN1-NMDAR (tagged with commercial anti-GluN1 antibody). Noteworthy, very 
few unspecific trajectories were detected in absence of anti-NMDAR IgG (Figure 2C). The 
mean square displacement (MSD) curve, an indicator of the surface explored by the targeted 
membrane receptor, and the instantaneous diffusion coefficients from the positive and 
weakly positive patients were indistinguishable, and not different to those of endogenous 
GluN1-NMDAR (Figure 2D). These data are consistent with the binding of QD-human IgG 
complexes to NMDAR because the presence of IgG against other neuronal membrane 
neurotransmitter receptors will provide different diffusion signatures (15, 16). As an example, 
IgG against dopamine receptors, reported in few FEP patients (17), would have different 
diffusion coefficient and MSD curve (18). Together, these data indicate that single 
nanoparticle imaging provides a quantitative diagnosis, and limits the human bias inherent to 
the CBA scoring step, constituting a powerful and alternative detection tool. 
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Discussion 
The field of “autoimmune psychiatry” is contentious with different results from different 
laboratories in Europe and the USA.  Here, in a coded study of 298 patient sera, we found a 
small proportion (around 5%) of patients with FEP that were positive for autoantibodies 
against the NMDAR. The NMDAR-Ab were effectively detected using live cell-based assays, 
and confirmed by single nanoparticle imaging. These results support earlier studies (19, 20), 
and further highlight the need to define the role of NMDAR-Ab in the etiology of the disease. 
While the hypothesis of a subgroup of psychotic patients associated with anti-brain antibodies 
is not novel per se, recent studies have rekindled discussion about the immune hypothesis of 
psychiatric disorders. Over the last decade, several studies have reported the presence of 
circulating NMDAR-Ab in varying proportions of patients with psychosis-related disorders (21-
24); however, several other studies have reported contradictory outcomes (6-8, 25). Such 
discrepancies could reflect the heterogeneity of autoantibody detection methods between 
studies (9, 26). We here confirmed that the choice of cell-based assay (e.g. live versus fixed 
cells) substantially influences the outcome of NMDAR-Ab seropositivity. In particular, the fixed 
CBA showed low sensitivity (2/14) and might be more suitable for patients with full-blown 
anti-NMDAR encephalitis, as virtually all seropositive samples from patients with FEP detected 
using live CBA were negative using this method. Live CBA appears to be more sensitive as it 
detected NMDAR-Ab in various clinical conditions (first-episode psychosis and encephalitis) 
and provided homogenous outcomes despite the human bias that falls to the visual scoring 
system. In addition, CBA employing live mammalian cells have the advantage of exposing 
autoantibodies to extracellular domains of receptors in a native conformation, consistent with 
the pathological condition. To note, each CBA has its own technical specificity, which call for 
caution when establishing strict comparisons. For instance, transfecting HEK cells with two 
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(e.g. lab A) or three (e.g. lab B) plasmids can generate different expression profile and 
detection in the cells, potentially influencing the relative detection rate. It should also be 
stressed out that the conformation of NMDARs in the human brain may be different from the 
one in HEK cells, or even rodent neurons. Testing the reactivity of NMDAR-Ab in human or 
primate brain tissue will surely be of great value for our understanding of these autoimmune 
disorders. 
 In search of a new approach that could identify the presence of NMDAR-Ab at low titers,  we 
performed an additional live test using single nanoparticle imaging in hippocampal neurons to 
define the live “signature”, i.e. the diffusion regime of the autoantibodies’ membrane target. 
We could show that the signature of the CBA defined “NMDAR-Ab” was indistinguishable 
from that of native GluN1-NMDAR. In particular, single nanoparticle imaging relies on 
individual antibodies binding to their target and is therefore independent of the sample titer, 
contrary to other methods which are dependent on their being sufficient antibodies to 
provide a detectable signal.  By taking advantage of this imaging approach, we were able to 
detect the presence of NMDAR-Ab in low titer samples (weak positives). Implementing such 
an additional approach in the clinical diagnostic would thus be of great help, although such a 
cutting-edge imaging method is technically challenging and time-consuming. Emerging assays 
with high-screening capacity single molecule-based approaches, such as PALM or uPAINT, and 
automatized fluorescence reading devices will likely provide efficient, sensitive and 
reproducible antibody detection tests. Since neurotransmitter receptors have distinct 
diffusion characteristics in the plasma membrane of neurons these approaches could even 
reveal the nature of the targeted receptors (15). Thus, the development of multi-approach 
screening methods, including CBA and cutting-edge single molecule detection methods, and 
clinical investigations will certainly shed new and key lights on the link between 
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autoantibodies and psychotic disorders in subsets of patients. Investigating in vivo the 
pathogenicity of these NMDAR-Ab is surely needed for our understanding of these 
pathologies, potentially raising hope for appropriate therapeutic strategies.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
References 
 
1. Crisp SJ, Kullmann DM, Vincent A (2016): Autoimmune synaptopathies. Nat Rev Neurosci. 17:103-117. 
2. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011): Clinical 
experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 10:63-74. 
3. Dalmau J, Geis C, Graus F (2017): Autoantibodies to Synaptic Receptors and Neuronal Cell Surface 
Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev. 97:839-887. 
4. Pollak TA, Beck K, Irani SR, Howes OD, David AS, McGuire PK (2016): Autoantibodies to central nervous 
system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. 
Psychopharmacology (Berl). 233:1605-1621. 
5. de Witte LD, Hoffmann C, van Mierlo HC, Titulaer MJ, Kahn RS, Martinez-Martinez P, et al. (2015): 
Absence of N-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia: The Importance of Cross-
Validation Studies. JAMA Psychiatry. 72:731-733. 
6. Haussleiter IS, Emons B, Schaub M, Borowski K, Brune M, Wandinger KP, et al. (2012): Investigation of 
antibodies against synaptic proteins in a cross-sectional cohort of psychotic patients. Schizophr Res. 140:258-
259. 
7. Masopust J, Andrys C, Bazant J, Vysata O, Kuca K, Valis M (2015): Anti-NMDA receptor antibodies in 
patients with a first episode of schizophrenia. Neuropsychiatr Dis Treat. 11:619-623. 
8. Rhoads J, Guirgis H, McKnight C, Duchemin AM (2011): Lack of anti-NMDA receptor autoantibodies in 
the serum of subjects with schizophrenia. Schizophr Res. 129:213-214. 
9. Sinmaz N, Amatoury M, Merheb V, Ramanathan S, Dale RC, Brilot F (2015): Autoantibodies in 
movement and psychiatric disorders: updated concepts in detection methods, pathogenicity, and CNS entry. 
Ann N Y Acad Sci. 1351:22-38. 
10. Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, et al. (2012): Disrupted surface 
cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 135:1606-1621. 
11. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. (2010): Antibodies to Kv1 
potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated 
protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 133:2734-2748. 
12. Hansen HC, Klingbeil C, Dalmau J, Li W, Weissbrich B, Wandinger KP (2013): Persistent intrathecal 
antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis. JAMA 
Neurol. 70:117-119. 
13. Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J (2007): Effects of anti-
glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol. 61:544-551. 
14. Groc L, Choquet D, Stephenson FA, Verrier D, Manzoni OJ, Chavis P (2007): NMDA receptor surface 
trafficking and synaptic subunit composition are developmentally regulated by the extracellular matrix protein 
Reelin. J Neurosci. 27:10165-10175. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
15. Groc L, Choquet D (2008): Measurement and characteristics of neurotransmitter receptor surface 
trafficking (Review). Mol Membr Biol. 25:344-352. 
16. Levi S, Triller A (2006): Neurotransmitter Dynamics. In: Kittler JT, Moss SJ, editors. The Dynamic 
Synapse: Molecular Methods in Ionotropic Receptor Biology. Boca Raton (FL). 
17. Pathmanandavel K, Starling J, Merheb V, Ramanathan S, Sinmaz N, Dale RC, et al. (2015): Antibodies to 
surface dopamine-2 receptor and N-methyl-D-aspartate receptor in the first episode of acute psychosis in 
children. Biol Psychiatry. 77:537-547. 
18. Ladepeche L, Dupuis JP, Bouchet D, Doudnikoff E, Yang L, Campagne Y, et al. (2013): Single-molecule 
imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors. Proc Natl Acad Sci U S 
A. 110:18005-18010. 
19. Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, et al. (2017): Prevalence 
and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control 
study. Lancet Psychiatry. 4:42-48. 
20. Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, et al. (2011): Disease-relevant 
autoantibodies in first episode schizophrenia. J Neurol. 258:686-688. 
21. Castillo-Gomez E, Oliveira B, Tapken D, Bertrand S, Klein-Schmidt C, Pan H, et al. (2016): All naturally 
occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of 
epitope and immunoglobulin class. Mol Psychiatry. 
22. Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. (2014): Seroprevalence of 
autoantibodies against brain antigens in health and disease. Ann Neurol. 
23. Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, et al. (2013): Neuropsychiatric 
disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. 
Mol Psychiatry. 
24. Endres D, Perlov E, Baumgartner A, Hottenrott T, Dersch R, Stich O, et al. (2015): Immunological 
findings in psychotic syndromes: a tertiary care hospital's CSF sample of 180 patients. Front Hum Neurosci. 
9:476. 
25. Busse S, Busse M, Brix B, Probst C, Genz A, Bogerts B, et al. (2014): Seroprevalence of N-methyl-D-
aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders 
and in dementia patients. Eur Arch Psychiatry Clin Neurosci. 
26. Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS (2013): Prevalence of anti-N-methyl-d-
aspartate (NMDA) antibodies in patients with schizophrenia and related psychoses: a systematic review and 
meta-analysis. Psychol Med.1-13. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
Author Contributions 
Drs Groc and Leboyer had full access to all of the data in the study and take responsibility for 
the integrity of the data and the accuracy of the data analysis. Jézéquel, Lepleux, Gréa, 
Rogemond, and Pollak contributed equally to this work. All authors reviewed and approved 
the final version of the manuscript. Study concept and design: McGuire, Honnorat, Leboyer, 
Groc. Acquisition, analysis, or interpretation of data: Jézéquel, Gréa, Rogemond, Pollak, 
Lepleux, Jacobson, Groc. Drafting of the manuscript: Jézéquel, Groc. Critical revision of the 
manuscript for important intellectual content: Jézéquel, Pollak, Vincent, Honnorat, McGuire, 
Leboyer, Groc. Statistical analysis: Jézéquel, Groc. Obtained funding: McGuire, Leboyer, 
Groc. Study supervision: Jézéquel, Leboyer, Groc. 
 
Financial Disclosure 
A.V. and the University of Oxford hold patents for antibody assays and A.V. receives a 
proportion of royalties. The other authors report no biomedical financial interests or 
potential conflicts of interest.  
 
Acknowledgments  
This study was supported by European Commission within the 7th Program (HEALTH-F2-
2010-242114), Agence Nationale de la Recherche Scientifique (ANR 12 SAMA 01401; 
Leboyer, Honnorat, Groc), Centre National de la Recherche Scientifique (Jézéquel, Gréa, 
Lepleux, Groc), IDEX Bordeaux (Jézéquel, Groc), Fondation FondaMental (Leboyer, Groc), 
Fondation Recherche Médical (Groc, Jézéquel, Leboyer). We thank Delphine Bouchet and 
Pauline Durand (Interdisciplinary Institute for Neuroscience, Bordeaux) for technical 
assistance on hippocampal cell cultures and Michael Chou (University College London, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
Department of Neuroimmunology) for his participation as a third blind scorer for Lab C 
detection tests. We also thank the OPTiMiSE consortium for constructive discussions and Dr. 
Brian Broberg for comments on the manuscript.  
 
 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
Figure legends 
 
Figure 1. Comparison of live versus fixed cell-based assays for NMDAR-Ab detection in the 
serum of first-episode psychotic patients. (A) Comparative scheme illustrating the different 
steps of the cell-based assays (CBA) performed in the 3 independent laboratories included in 
the study. Note the relative homogeneity between Lab A and Lab B protocols, compared to 
the detection test performed in Lab C, but Lab B includes an additional step for confirmation 
of IgG specificity. (B) Representative images of the live CBA performed in Lab A. GluN1-
GFP/GluN2B-expressing HEK293 cells (“GFP”, green) were incubated with purified IgG from 
first-episode psychotic (first ep.) patients’ sera (“IgG”, red). Note the presence of transfected 
cells binding patients’ purified IgG (white arrowheads), illustrating the detection of positive 
and weak positive sera. Samples from patients with known anti-NMDAR encephalitis 
(“enceph.”) were used a positive control. Scale bar= 50 µm. (C) Table summarizing the 
number of samples scored as “positive” and “weak positive” relative to the type of CBA (live 
or fixed CBA, serum or purified IgG) and the laboratory that performed the detection test. 
The number of total seropositive samples dramatically decreases when sera are submitted 
to the fixed CBA. (D) Comparison and correlation of the test scores between Lab A and Lab B 
(x-axis, binding score from Lab A; y-axis, dilution beyond which binding was no longer 
positive from Lab B).  
 
Figure 2. Single nanoparticle imaging to detect circulating NMDAR-Ab. Schematic description 
of a single nanoparticle imaging experiment for the detection of NMDAR-Ab at the surface of 
cultured hippocampal neurons. (A) First, purified IgG from first-episode psychotic patient are 
directly coupled to functionalized QD (anti-human Fab fragment) at a ratio 1:1. Live 
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hippocampal neurons are then incubated for 10 min with single QD-purified IgG complexes 
which will bind to the NMDAR. (B) Single QD-purified IgG complexes, attached to the 
NMDAR membrane target, are then detected and tracked over 500 frames with a 20Hz 
frequency of acquisition. By fitting the fluorescence signal to a 2D Gaussian function, QD-
purified IgG complexes can be localized with a pointing accuracy of 10-30 nm. The surface 
density of nanofluorescent particles must be low enough to ensure good spatial resolution. 
(C) The different trajectories collected over the 500 frames are then reconnected. Left upper 
panel: Neuronal field with representative trajectories of the membrane target bound to QD-
purified IgG. Scale bar= 20µm. Right panel: Enlarged single trajectories (25s duration) of the 
surface receptors targeted by endogenous surface GluN1-NMDAR (anti-GluN1 subunit 
antibody), purified IgG from seropositive patients (“positive”, 5 µg/ml), purified IgG from 
weak seropositive patients (“Weak positive”, 5 µg/ml) or negative control without primary 
IgG. Scale bar= 500 nm. (D) Diffusion parameters are finally extracted from QD-purified IgG 
trajectories for quantification. Left panel: comparison of the mean square displacement 
(MSD) curves obtained with five patients’ purified IgG (2 positive and 3 weakly positive) or 
anti-GluN1 subunit antibody (mean ± SEM; Positive, n= 2012 trajectories; weak positive, n= 
1409 trajectories; endogenous GluN1, n=113). Right panel: comparison of the mean 
instantaneous diffusion coefficients (µm
2
/s) between positive, weak positive and 
endogenous GluN1-NMDAR surface trajectories (mean ± SEM; positive= 0.16 ± 0.015, n=175 
trajectories randomly selected from 2012 trajectories; weak positive= 0.17 ± 0.016, n=180 
randomly selected from 1409 trajectories; endogenous GluN1= 0.15 ± 0.016, n=113; ANOVA 
followed by Newman-Keuls comparison test; 3 independent experiments; no statistical 
difference between groups). To note, same statistical conclusion is reached when comparing 
initial dataset (Positive= n= 2012 trajectories; weak positive, n= 1409 trajectories; 
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endogenous GluN1, n=113; ANOVA followed by Newman-Keuls comparison test; no 
statistical difference between groups).  
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table. Demographics, Diagnostic, and comparison between seropositive and -negative patients 
 
 
Cohort Seropositive Seronegative 
Patients, No. 298 14 (4.7%) 284 (95.3%) 
Age, mean (SD) 
26.06 
(5.97) 
26.77 
(6.61) 
26.02 
(5.95) 
Sex, No. (percent) 
Male 196 
(65.8%) 
Female 102 
(34.2%) 
Male 8 (57.1%) 
Female 6 (42.9%) 
Male 188 (66.2%) 
Female 96 (33.8%) 
Duration of psychosis (mo.), 
mean (SD) 
5.91 (5.89) 4.23 (6.44) 5.99 (5.86) 
DSM-IV diagnosis, No. (percent) 
Schizophreniform disorder 131 (44 %) 6 (42.9%) 125 (44%) 
Schizophrenia undiff. type 28 (9.4%) 2 (14.3%) 26 (9.2%) 
Schizophrenia disorganised type 6 (2%) 1 (7.1 %) 5 (1.8%) 
Schizophrenia paranoid type 110 (36.9%) 5 (35.7 %) 105 (37%) 
Schizophrenia residual type 1 (0.3%) 0 (0%) 1 (0.4 %) 
Schizoaffective disorder 21 (7.0 %) 0 (0 %) 21 (7.4 %) 
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